Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Immunotoxin - a new treatment option in patients with relapsed and refractory Hodgkin lymphoma
Avtorji:ID Jezeršek Novaković, Barbara (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (520,10 KB)
MD5: 5524559F25771036838674B23734AAC6
 
Jezik:Angleški jezik
Tipologija:1.02 - Pregledni znanstveni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Povzetek:Background. Even though Hodgkin lymphoma is a highly curable disease, some of the patients have either a refractory disease or experience a relapse following a successful primary therapy. Durable responses and remissions in patients with relapsed or refractory disease may be achieved in approximately one-half with salvage chemotherapy followed by high dose chemotherapy (HDT) and autologous hematopoietic cell rescue (SCT). On the other hand, patients who relapse after HDT and autologous SCT or those who have failed at least two prior multi-agent chemotherapy regimens and are not candidates for HDT have limited treatment options. Conclusions. A new treatment option in this population is an immunotoxin Brentuximab vedotin composed of a CD30 directed antibody linked to the antitubulin agent monomethyl auristatin E. It has demonstrated a substantial effectiveness and an acceptable toxicity. In the pivotal study, the overall response rate was 75% with 34% of complete remissions. The median durations of response were 20.5 and 6.7 months for those with complete remission and all responding patients, respectively. The median overall survival was 40.5 months (3-years overall survival 54%) and the median progression-free survival 9.3 months. The most common non-hematologic toxicities were peripheral sensory neuropathy, nausea, and fatigue while the most common severe side effects were neutropenia, thrombocytopenia, anemia, and peripheral sensory neuropathy.
Ključne besede:immunotoxin, Hodgkin lymphoma, toxicity, new treatment option
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:01.12.2015
Založnik:Association of Radiology and Oncology
Leto izida:2015
Št. strani:str. 315-319, I
Številčenje:Vol. 49, no. 4
Izvor:Ljubljana
PID:20.500.12556/DiRROS-18789 Novo okno
UDK:616.4-006-085
ISSN pri članku:1318-2099
DOI:10.1515/raon-2015-0036 Novo okno
COBISS.SI-ID:2078075 Novo okno
Avtorske pravice:by Authors
Datum objave v DiRROS:22.04.2024
Število ogledov:773
Število prenosov:520
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Radiology and oncology
Skrajšan naslov:Radiol. oncol.
Založnik:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 Novo okno

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:imunotoksini, Hodgkinov limfom, kemoterapija, toksičnost


Nazaj